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Introduction
Although beta-blocking agents have come to play an important role in the treatment of hypertension and coronary heart disease, their use is associated with a number of undesirable effects. General problems include bronchoconstriction, metabolic disturbances and cerebral effects; as regards the cardiovascular system, they result in reduction in heart rate, increase of peripheral (and coronary) vascular resistance and impairment of cardiac conduction, and myocardial contractility. Since many of these unwanted effects result from blockade of beta-2 receptors, a second generation of 'cardioselective' beta-blockers arose, with predominantly beta-1 blocking activity. However, such selectivity is never complete and, in any event, the unwanted cardiac effects of beta blockade (particularly negative inotropism) would remain even with a pure beta-1 blocking agent.
There has thus been a search for an 'ideal' drug 1 '" 2 ', leading to the emergence of a third-generation of beta blockers. The ideal agent would have selective beta-1 blocking activity, combined with beta-2 agonistic and vasodilating effects. It would also reduce blood pressure, heart rate and left ventricular pre-load (both at rest and on exercise), leading to a reduction in myocardial oxygen consumption and would not have unwanted effects such as bronchoconstriction, peripheral vasoconstriction or myocardial depression' Celiprolol is an example of a third-generation betablocker developed in an attempt to approach this ideal' 21 . Its beta antagonistic activity is primarily seen at beta-1 receptors, whilst it has also been demonstrated to have beta-2 agonist activity' 31 . Since these features suggest that celiprolol should be a useful drug for the treatment of coronary artery disease and hypertension, we have carried out a study to investigate the haemodynamic effects of this drug in patients with both these pathologies.
Patients and methods

PATIENTS
Thirty male patients took part in this study; their mean age was 49-5 (range 35-62) years. All had angiographically demonstrated symptomatic coronary artery disease (Grade II or greater, Canadian classification; NYHA Grade I) and hypertension (WHO 1959) , of at least one year's standing. None of these patients had primarily valvular heart disease, recent myocardial infarction or unstable angina pectoris at the time of the study. All patients gave their informed consent to participate in the study. The patients were randomized into two treatment groups, one to receive celiprolol (N = 16) and the other to receive metoprolol (N = 14). These two groups were wellmatched with respect to all features, except for global ejection fraction and myocardial oxygen consumption (Tables 1, 2 and 5a). Mean (SD) global ejection fraction was 63-4% (12%) in the celiprolol group and 56-9% (11-9%) in the metoprolol group (/><005); mean (SD) myocardial oxygen consumption was 8-2 (3-9) ml.min ' in the celiprolol group and 12-2 (3-4) ml.min"' in the metoprolol group (/*< 0-006).
PROCEDURES
All normal medication was withheld on the study day and for a period prior to the study so that the pharmacokinetic properties of the drug could be eliminated from the body.
A Millar-tip catheter (high speed lumen, SPC 484A) was inserted into the left ventricle via a femoral artery for measurement of left ventricular pressure and dp/dt, together with ECG and the actual angiographic frame markers (4-channel tape memory system HP 3960). A pigtail catheter (F6) was inserted, via the other femoral artery, into the thoracic aorta for arterial blood pressure measurement. A preformed sheath (F10) designed by ourselves' 41 was inserted via a femoral vein into the coronary sinus and a thermodilution catheter (Milton-Webster) introduced through this into the great cardiac vein; its position was repeatedly verified by contrast injection. The electrocardiogram was monitored continuously during the study.
All measurements were undertaken with the patient in the supine position. Ten minutes after instrumentation, baseline haemodynamic measurements were carried out. Contrast high-speed left cine-ventriculography (50 frames s" 1 ) was then performed in the 30-degree right anterior oblique position, utilizing 40 ml isopromid ('Ultravist 300') injected at a rate of 12 ml.s" 1 . After a further interval of at least 15 min, the haemodynamic measurements were repeated and study medication was not administered unless the measurements (particularly left ventricular end-diastolic pressure) were stable, to avoid uncontrolled changes caused by the contrast agent.
Study medication was then administered, in a doubleblind fashion according to a predetermined randomization code. Patients received either celiprolol or metoprolol 0-15mg.kg~' as an intravenous infusion over a period of 5 min.
Twenty minutes after drug administration, the haemodynamic measurements were repeated, followed by a further left ventriculogram. The study was then completed by the performance of selective coronary angiography.
PROCESSING OF DATA
The isovolumic relaxation phase of the cardiac cycle was quantified by determination of a time constant ('T') by extrapolation from the left ventricular pressure-time curve. This calculation was based on the period 10-80 ms after dp/dt min [51 digitizing the P-signals in 2-5 ms time intervals (HP 9825A).
Sinus-node single-cardiac cycle analysis was undertaken on the 50 frames s~' left ventricular angiograms using the Angiographic Dynamic System (AVD, Siemens). The start point of left ventricular pressure increase was defined as the end-diastolic volume (LVEDV), whereas the smallest volume was determined as left ventricular end-systolic volume (LVESV). The corresponding pressure relating to these volumes was defined as left ventricular end-diastolic and end-systolic pressure (LVEDP resp. LVESP). Standard indices were derived. Stroke volume was derived from LVEDV and LVESV; cardiac output was calculated from stroke volume and heart rate. Cardiac output, stroke volume and left ventricular volumes were indexed to body surface area in the standard manner (CI, SVI, LVEDVI and LVESVI respectively).
Peak filling rate (PFR) and the time to peak filling rate (TPFR) were both normalized with respect to both LVEDV and heart rate. Eight different short axes and the long-axis were determined (floating axis centre point) frame by frame as a measure of regional contractile behaviour.
From synchronously obtained pressure-volume data (the volumes were analysed every 20 ms using modified area-length method) pressure-volume (P-V) loops were constructed. The pressure-volume-time synchronization was realized from registration of left ventricular pressure and the actual angiographic frame marker simultaneously (tape memory system HP 3960). Left ventricular work was obtained from the area of the (P-V) loops and defined in Newton m (Nm). To avoid distortion of the P-V curves during drug-induced changes in heart size and afterload, these were normalized according to LVESV Great cardiac vein blood flow ('CSF') was measured continuously by thermodilution. Coronary venous blood samples were obtained for measurement of haemoglobin, lactate, pH, pOj, and myocardial oxygen consumption was estimated from these data. Coronary resistance (CR) was also estimated using these data, together with the simultaneous aortic pressure and the right atrial pressure measured at the start of the study.
STATISTICS
The significance of within-group changes, betweengroup differences and mean differences (%) were determined by application of Wilcoxon signed ranks tests and Mann-Whitney tests respectively. The significance level was specified as P = 005. When P ranged between 005 and 01 (0-05 </>< 0-1) these situations were reported as such; whereas results with P >01 are reported as nonsignificant (NS).
Results
Haemodynamic results are summarized in Tables 2  and 3 . Following celiprolol (C) administration, there were significant improvements in mean (SD) LVESVI (from 28 (13) to 25 (11) mLm" 2 , /><005) and ejection fraction (from 63-4 (120) to 65-5 (12-2) %, P<005), whilst improvements in LVEDP, peak filling rate, systolic ejection rate and the time constant T approached significance (0-05 </>< 0-1). After metoprolol (M), there were significant reductions in cardiac index (from 304 (0-79) to 2-62 (0-72) l.min-'.m" 2 ,/ ) <005), ejection fraction (from 56-9 Cl 1-9) to 550 (12-7) %, /><005) and mean circumferential fibre shortening velocity (from 0-83 (0-28) to 0-73 (0-26) circumferences per second, P< 001), whilst an increase in peripheral resistance approached significance Heart rate fell following metoprolol administration from 69 (9) to 64 (9) min" 1 (/ > <005) but showed no significant change following celiprolol. Aortic blood pressure showed similar, small and non-significant, reductions following both drugs (005 < P < 0-10).
The mean differences (median) (%) of the various haemodynamic reaction routes following celiprolol (C) or metoprolol (M) administration are listed in Table 3 . There -36-7) , whilst the reactions in LVEDP and total peripheral resistance approached significance (0-05 < P < 0-1). Figure 1 is an example of a left ventricular P-V loop from a celiprolol-treated patient, normalized for LVESV. In five patients, celiprolol treatment resulted in a shift to the left of the loop and an increased slope in the relaxation phase after the LVESP/LVESV intercept. In contrast, right shifts of the loop and reductions in slope were seen in five patients after metoprolol administration; this drug did not produce shifts to the left or an increased slope in the relaxation phase (as seen in the five celiprolol-treated patients) in any of the cases. Results of regional wall motion measurements (for eight myocardial regions in both short axes and the long axis) are summarized in Table 4 . Following celiprolol administration, significant changes were not seen in any of the regions. Following metoprolol, there was a significant deterioration in region 7 (P < 005), whilst in region 6 the deterioration approached significance (P<0-1) .
Measurements of coronary flow and myocardial oxygen consumption are summarized in Tables 5(a) and (b). Both drugs resulted in similar increases in coronary flow (P<005), myocardial oxygen consumption (celiprolol P<0-0\; metoprolol P<005)and decreases in coronary resistance (celiprolol 005 < P < 0-1, metoprolol P < 005). The myocardial oxygen consumption following celiprolol administration increased from 8-23 (3-94) to 10-81 (6-34) ml.min"'. The mean differences (before and after) between celiprolol and metoprolol revealed no significant deviation (Table 5( b) ). Considering the severity of coronary artery disease (related to numerical scoring of lesions, their frequency, location and grades of obstruction) the increased myocardial oxygen consumption was seen in patients with the most severe coronary artery disease (coronary score > 40) in both the celiprolol (7-6 (4-3) to 9-9 (5-3) ml.min"'; P<00l) and metoprolol groups (12 9 (21) to 15-8 (4-6) ml.min" 1 ; P<005). In addition the increase in coronary sinus flow was focused on these selected groups (coronary score >40) (127 (69) to 153 (88) ml.min-1 , P<006 in the celiprolol group; 118 (47) to 156 (87) ml.min" 1 ; /><008 in the metoprolol group. The JPdV, which may be related to the external work was reduced in the metoprolol group (0-93 (0-20) to 0-80 (0-22) Nm) and enhanced in the celiprolol group (0-88 (0-25) to 100 (0-28) Nm), but without significance. However, the mean differences of these reactions revealed significant deviations (P<00l).
Discussion
Celiprolol is a new molecule with haemodynamic and metabolic properties which differ from those of other betablockers. The combination of hypertension, coronary 
Greatcardiac vein flow; ml.min" heart disease and cardiac dysfunction (systolic and/or diastolic) is common and it is important that these patients are treated with drugs which do not have undesirable effects on left ventricular function. This study investigated the effects of single intravenous doses of celiprolol and metoprolol on resting haemodynamics in patients with coronary artery disease and hypertension. The groups were well-matched in terms of haemodynamic indices and the doses of drugs used were chosen so as to produce substantial haemodynamic effects.
The results obtained in terms of global left ventricular function confirm previous reports. Silke et al. reported comparative dose-response studies of celiprolol and atenolol' 71 and also evaluated celiprolol in patients with coronary artery disease' 81 . They found that, whilst atenolol reduced heart rate, cardiac output and ejection fraction, and increased peripheral resistance, celiprolol resulted in significant increase of cardiac output and ejection fraction without any consistent changes in heart rate, LVEDP or peripheral resistance. Gensini et a/.' Our study has demonstrated the favourable effects of celiprolol on left ventricular systolic function and also the failure of celiprolol to produce the marked increase in peripheral resistance seen with metoprolol and many other beta-blockers' 310131819 '. Diastolic myocardial function can be just as important as systolic function, particularly in patients with left ventricular hypertrophy due to hypertension' 2021 '. This part of the cardiac cycle is load-dependent and an active oxygen-consuming process; abnormalities of diastolic function are seen in coronary artery disease and hypertensive heart disease. Our study has demonstrated that, whilst metoprolol did not produce significant changes in diastolic function, celiprolol resulted in improvement.
The numerical data relating to diastolic function were confirmed by the appearance of the left ventricular P-V loops. Metoprolol resulted in either no change or a shift to the right, with a reduced slope in the early relaxation phase (the part of the P-V loop just after the LVESP/ LVESV intercept); in contrast, five celiprolol-treated patients showed a leftward shift of the loop combined with a higher slope in the early relaxation phase of the loop.
The prolongation of diastole associated with reduced heart rate would be expected to increase coronary blood flow after beta-blocker administration. However, a reduction in coronary flow and myocardial oxygen consumption has been reported following propranolol administration' 22 " 24 ' and cardioselectivity should not influence such effects on the coronary circulation' 10 '. In the present study, both celiprolol and metoprolol increased coronary sinus flow as well as myocardial oxygen consumption, although the effects of the two drugs on left ventricular function were very different. Afterload, referred to as mean aortic pressure, preload and heart rate remained constant throughout the investigation period in both groups; the wall stress was unchanged or significantly reduced (metoprolol), the external work, related to JPdV was insignificantly increased after celiprolol and reduced after metoprolol administration. Consequently, after drug intervention in both groups unchanged or reduced myocardial oxygen consumption should be expected. Although the data suggest a minor increase in contractility (enhanced ejection fraction and shifts to the left of the P-V loops in five patients after celiprolol), these minor changes are unable to explain the enhanced oxygen consumption in the celiprolol group alone. These data suggest that myocardial efficiency might be diminished especially in morphologically very severe coronary artery disease and hypertension, but, additional studies are necessary to exclude methodological limitations (e.g. long-acting influence of contrast material).
Further studies are in progress to determine the haemodynamic effects and myocardial efficiency of celiprolol on subgroups of patients with different left ventricular masses, in order to ascertain whether haemodynamic responses are influenced by the presence and severity of left ventricular hypertrophy.
